Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.38 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | SCN1A | P35498 | 1/20 | 0.34 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.34 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.34 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.33 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | ANPEP | P15144 | 2/20 | 0.32 |
| ▸ | ERAP2 | Q6P179 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4919308 | 0.78 | — | — | |
| SCHEMBL7024181 | 0.77 | KCNH2 (0.40) | GRIN2B | |
| Hydrochloric Acid SCHEMBL2656164 | 0.76 | — | — | |
| SCHEMBL939870 | 0.74 | DRD3 (0.42) | — | |
| SCHEMBL172662 | 0.74 | KDM4E (0.58) | SMYD3EPHX1KDM4ECYP1A2LMNA | |
| SCHEMBL6986244 | 0.74 | — | — | |
| SCHEMBL8275616 | 0.73 | DRD2 (0.39) | — | |
| SCHEMBL28283920 | 0.72 | MAOA (0.50) | — | |
| SCHEMBL7775092 | 0.72 | KDM4E (0.62) | EPHX1KDM4ECYP1A2LMNACYP2D6 | |
| SCHEMBL1043149 | 0.72 | KDM4E (0.62) | EPHX1KDM4ECYP1A2LMNACYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3495341-B1 | PREPARATION PROCESS OF PERFLUOROALKYL COMPOUND WITH MONOHYDROPERFLUOROALKANE AS STARTING MATERIAL | KANTO DENKA KOGYO KK (JP) | 2022-11-02 | — | — | EP | disclosed |
| CN-109563016-B | Method for producing perfluoroalkyl compound using monohydroperfluoroalkane as starting material | 关东电化工业株式会社 | 2022-05-13 | — | — | CN | disclosed |
| US-10450253-B2 | Preparation process of perfluoroalkyl compound with monohydroperfluoroalkane as starting material | KANTO DENKA KOGYO CO., LTD. (JP) | 2019-10-22 | — | — | US | disclosed |
| EP-3495341-A1 | METHOD FOR PRODUCING PERFLUOROALKYL COMPOUND USING MONOHYDROPERFLUOROALKANE AS STARTING MATERIAL | Kanto Denka Kogyo Co., Ltd. (JP) | 2019-06-12 | — | — | EP | disclosed |
| US-20190169107-A1 | PREPARATION PROCESS OF PERFLUOROALKYL COMPOUND WITH MONOHYDROPERFLUOROALKANE AS STARTING MATERIAL | NATIONAL UNIVERSITY CORPORATION GUNMA UNIVERSITY (JP) | 2019-06-06 | — | — | US | disclosed |
| CN-109563016-A | Using single hydrogen perfluoro alkane as the manufacturing method of the all-fluoroalkyl compound of starting material | 关东电化工业株式会社 | 2019-04-02 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190169107-A1 | PREPARATION PROCESS OF PERFLUOROALKYL COMPOUND WITH MONOHYDROPERFLUOROALKANE AS STARTING MATERIAL | PFKFB1, PFKFB4, PFAS | SMYD3 2712/4885EPHX1 554/4885KDM4E 502/4885 |
| US-10450253-B2 | Preparation process of perfluoroalkyl compound with monohydroperfluoroalkane as starting material | PFKFB1, PFKFB4, PFAS | SMYD3 2712/4885EPHX1 554/4885KDM4E 502/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.